Equities researchers at Canaccord Genuity Group began coverage on shares of Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage set a “buy” rating and a $6.00 price target on the stock.
Sigilon Therapeutics Stock Up 14.7 %
Shares of Sigilon Therapeutics stock opened at $0.63 on Wednesday. The company has a quick ratio of 2.64, a current ratio of 2.64 and a debt-to-equity ratio of 0.31. Sigilon Therapeutics has a 12 month low of $0.29 and a 12 month high of $2.09. The business has a fifty day simple moving average of $0.39 and a 200 day simple moving average of $0.55. The stock has a market cap of $20.44 million, a PE ratio of -0.37 and a beta of 0.14.
Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.16. Sigilon Therapeutics had a negative return on equity of 91.82% and a negative net margin of 444.44%. The firm had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $2.45 million. Research analysts predict that Sigilon Therapeutics will post -1.6 EPS for the current year.
Institutional Inflows and Outflows
About Sigilon Therapeutics
Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.
- Get a free copy of the StockNews.com research report on Sigilon Therapeutics (SGTX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.